secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001193125-23-052344
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom reports Q4 net loss $55M; FDA meeting in March for vonoprazan resubmission
--------------------------------------------------------------------------------

- Net loss Q4 2022 $55.0M vs $35.8M Q4 2021; full year net loss $197.7M vs $143.9M.
- Cash $155.4M at Dec 31, 2022; additional $100M available under Hercules term loan.
- FDA meeting scheduled March 2023 to discuss stability data and resubmission for erosive GERD and H. pylori NDAs.
- Positive Phase 3 PHALCON-NERD-301 met primary endpoint (p<0.0001) for vonoprazan in non-erosive GERD.
- Commercial launch on hold due to nitrosamine impurity; mitigation measures in place.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523052344/0001193125-23-052344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523052344/d413841d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-052344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer